Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
03 May 1994Website:
http://www.nektar.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 5 min agoDividend
Analysts recommendations
Institutional Ownership
NKTR Latest News
SAN FRANCISCO , May 30, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences: Jefferies Healthcare Conference in New York City on Thursday, June 6, 2024 at 3:30 p.m. Eastern Time / 12:30 p.m.
Nektar Therapeutics (Nasdaq: NKTR) will release its first quarter 2024 financial results on May 9, 2024, after the close of U.S. financial markets. Howard Robin, President and CEO, will lead a conference call at 5:00 p.m. to discuss the results.
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?
SAN FRANCISCO , March 22, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m.
The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.
Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.
Nektar Therapeutics (NASDAQ:NKTR ) Q4 2023 Earnings Conference Call March 4, 2024 5:00 PM ET Company Participants Vivian Wu - Director, Investor Relations and Corporate Affairs Howard Robin - President and Chief Executive Officer Jonathan Zalevsky - Chief Research & Development Officer Sandra Gardiner - Chief Financial Officer Mary Tagliaferri - Chief Medical Officer Conference Call Participants Cheng Li - Oppenheimer & Co. Inc. Kambiz Yazdi - Jefferies Group LLC Jessica Fye - JPMorgan Chase & Co. Julian Harrison - BTIG Andy Hsieh - William Blair & Company Operator Good day, and thank you for standing by. Welcome to the Nektar Therapeutics Fourth Quarter 2023 Financial Results Conference Call.
Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.32 per share a year ago.
SAN FRANCISCO , Feb. 27, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in Boston on Tuesday, March 5, 2024 at 2:10 p.m. Eastern Time.
SAN FRANCISCO , Jan. 3, 2024 /PRNewswire/ -- Nektar (Nasdaq: NKTR) management is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 5:15 p.m.
- 1(current)
What type of business is Nektar Therapeutics?
Nektar Therapeutics is a research biopharmaceutical company. Founded in 1990 in California. Currently registered in Delaware in 1998. The company's activities are focused on the development of innovative drugs. Research and development include potential methods for treating cancer and autoimmune diseases. In the field of immuno-oncology, drugs are being developed to stimulate and support the body's immune response to fight cancer. The biological drug bempegaldesleukin (NKTR-214) is the main development in this area. In the treatment of autoimmune diseases, the company is developing the drug NKTR-358. The drug has undergone trials for the treatment of systemic lupus erythematosus, psoriasis, and atopic dermatitis. MOVANTIK is a drug for the treatment of constipation caused by opioids, a side effect of chronic use of prescription opioid analgesics.
What sector is Nektar Therapeutics in?
Nektar Therapeutics is in the Healthcare sector
What industry is Nektar Therapeutics in?
Nektar Therapeutics is in the Biotechnology industry
What country is Nektar Therapeutics from?
Nektar Therapeutics is headquartered in United States
When did Nektar Therapeutics go public?
Nektar Therapeutics initial public offering (IPO) was on 03 May 1994
What is Nektar Therapeutics website?
https://www.nektar.com
Is Nektar Therapeutics in the S&P 500?
No, Nektar Therapeutics is not included in the S&P 500 index
Is Nektar Therapeutics in the NASDAQ 100?
No, Nektar Therapeutics is not included in the NASDAQ 100 index
Is Nektar Therapeutics in the Dow Jones?
No, Nektar Therapeutics is not included in the Dow Jones index
When does Nektar Therapeutics report earnings?
The next expected earnings date for Nektar Therapeutics is 08 August 2024